Xeljanz Edges Humira Just a Bit for Real-World RA Patients, Study Suggests
Tofacitinib (Xeljanz) appeared ever-so-slightly more effective than adalimumab (Humira) for rheumatoid arthritis (RA) in a study that used real-world patient data to simulate a randomized head-to-head trial. Leaders of Australia’s OPAL network of rheumatologists reported that, among 699 RA patients starting their first biologic or targeted therapy for the disease, the mean 28-joint Disease Activity […]